2 completed, 2 terminated, 1 unknown. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 3 | Terminated 2, Unknown 1 |
Follow APG-1387: new trials by email Literature Review of APG-1387 trials Research Report on APG-1387
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma APG-1387 for Injection, Gemcitabine, Nab paclitaxel - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 21 | 2021-03-17 | 2026-01-08 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B APG-1387, Entecavir 0.5 mg - Hepatitis B, Chronic Hep B | Phase 2 | Unknown | Ascentage Pharma Group Inc. | 122 | 2020-06-03 | 2021-08-26 |
| Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors APG-1387 for Injection, Toripalimab - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 40 | 2020-04-10 | 2026-01-08 |
| APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B APG-1387 for Injection - Chronic Hepatitis B | Phase 1 | Completed | Ascentage Pharma Group Inc. | 49 | 2018-07-04 | 2021-11-08 |
| APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies APG-1387 for Injection - Advanced Solid Tumors or Hematologic Malignancies | Phase 1 | Completed | Ascentage Pharma Group Inc. | 90 | 2017-11-21 | 2023-02-01 |
Hepatitis B, Chronic (2) · Hematologic Neoplasms (1) · Hepatitis B (1) · Pancreatic Neoplasms (1)
Ascentage Pharma Group Inc. (5)
China (4) · United States (1)
Yifan Zhai, MD, PhD (3) · Yifan Zhai, M.D., Ph.D. (2)